ロード中...

HDACi mediate UNG2 depletion, dysregulated genomic uracil and altered expression of oncoproteins and tumor suppressors in B- and T-cell lines

BACKGROUND: HDAC inhibitors (HDACi) belong to a new group of chemotherapeutics that are increasingly used in the treatment of lymphocyte-derived malignancies, but their mechanisms of action remain poorly understood. Here we aimed to identify novel protein targets of HDACi in B- and T-lymphoma cell l...

詳細記述

保存先:
書誌詳細
出版年:J Transl Med
主要な著者: Iveland, Tobias S., Hagen, Lars, Sharma, Animesh, Sousa, Mirta M. L., Sarno, Antonio, Wollen, Kristian Lied, Liabakk, Nina Beate, Slupphaug, Geir
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2020
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7137348/
https://ncbi.nlm.nih.gov/pubmed/32264925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-020-02318-8
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!